Last update: March 19, 2007

Repaglinide

High Risk for breastfeeding


Poorly safe. Evaluate carefully.
Use safer alternative or interrupt breastfeeding several T½.
Read the Comment.

Meglitinide drugs stimulate secretion of endogen insulin.
There is a potential risk of hypoglucemia.
Oral anti-diabetic drugs are useless for treatment of diabetes type 1. For diabetes type 2, diet and exercise are advisable. Breastfeeding helps to lower glucemia level. See section on Maternal diabetes mellitus

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Tradenames

Main tradenames from several countries containing Repaglinide in its composition:

Pharmacokinetics

Variable Value Unit
Bioavailability 63 %
Molecular weight 453 daltons
Protein Binding 98 %
Tmax 1 hours
T1/2 1 hours

References

We are working to add the scientific references of this product. It will be available soon. If you wish to have access to this information, please let us know by leaving your comment in the opinion section below.

Total visits

1,516

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche de Euskadi

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM